While the clinical properties of these inhibitors remain to be assessed, it was reported that All‐trans retinoic acid, a drug used to treat promyelocytic leukemia expressing the PML‐RARα fusion protein, directly binds and inhibits PIN1, which may extend its use to other cancer types [156]. Here, PIN1 is linked to cancer.